Skip to main content
[Preprint]. 2025 Jul 10:2025.07.06.663368. [Version 1] doi: 10.1101/2025.07.06.663368

Fig. 7: H3K9AC marks the promoters of P53 and TOP1 in all breast cancer types. Human PDX HCI003 shows mild synergy when combined with neratinib and T-DXd.

Fig. 7:

(A-B) H3K9AC marks the promoters of p53, p73, ATM, KAP1, TOP1, TOP2A, TOP2B, and NPAT, but not p63 in all breast cancer types. H3K9me3 doesn’t mark the p53, p73, p63, ATM, KAP1, TOP1, TOP2A, TOP2B, and NPAT promoters in all breast cancer types. (C)The PDX tumor microarray of triple negative breast cancer showed increased H3K9AC IHC signal. (D)Tumor staining Allred score and H score of H3K9AC IHC signal from tumor microarray in Fig 7C. (E)The information of PDXO is in the TNBC PDX list. (F-G) Synergy of neratinib and T-DXd in human PDX of WHIM2, WHIM12, and WHIM30. (H) The in vivo treatment of the WHIM2 with neratinib and T-DXd.